論文

査読有り 筆頭著者 国際誌
2018年5月

Sustained clonal hematopoiesis by HLA-lacking hematopoietic stem cells without driver mutations in aplastic anemia.

Blood advances
  • Tatsuya Imi*
  • ,
  • Takamasa Katagiri*
  • ,
  • Kazuyoshi Hosomichi
  • ,
  • Yoshitaka Zaimoku
  • ,
  • Viet Hoang Nguyen
  • ,
  • Noriharu Nakagawa
  • ,
  • Atsushi Tajima
  • ,
  • Tetsuichi Yoshizato
  • ,
  • Seishi Ogawa
  • ,
  • Shinji Nakao. *equally contribution

2
9
開始ページ
1000
終了ページ
1012
記述言語
英語
掲載種別
DOI
10.1182/bloodadvances.2017013953

Clonal hematopoiesis by hematopoietic stem progenitor cells (HSPCs) that lack an HLA class I allele (HLA- HSPCs) is common in patients with acquired aplastic anemia (AA); however, it remains unknown whether the cytotoxic T lymphocyte (CTL) attack that allows for survival of HLA- HSPCs is directed at nonmutated HSPCs or HSPCs with somatic mutations or how escaped HLA- HSPC clones support sustained hematopoiesis. We investigated the presence of somatic mutations in HLA- granulocytes obtained from 15 AA patients in long-term remission (median, 13 years; range, 2-30 years). Targeted sequencing of HLA- granulocytes revealed somatic mutations (DNMT3A, n = 2; TET2, ZRSR2, and CBL, n = 1) in 3 elderly patients between 79 and 92 years of age, but not in 12 other patients aged 27 to 74 years (median, 51.5 years). The chronological and clonogenic analyses of the 3 cases revealed that ZRSR2 mutation in 1 case, which occurred in an HLA- HSPC with a DNMT3A mutation, was the only mutation associated with expansion of the HSPC clone. Whole-exome sequencing of the sorted HLA- granulocytes confirmed the absence of any driver mutations in 5 patients who had a particularly large loss of heterozygosity in chromosome 6p (6pLOH) clone size. Flow-fluorescence in situ hybridization analyses of sorted HLA+ and HLA- granulocytes showed no telomere attrition in HLA- granulocytes. The findings suggest that HLA- HSPC clones that escape CTL attack are essentially free from somatic mutations related to myeloid malignancies and are able to support long-term clonal hematopoiesis without developing driver mutations in AA patients unless HLA loss occurs in HSPCs with somatic mutations.

リンク情報
DOI
https://doi.org/10.1182/bloodadvances.2017013953
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/29720492
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5941997
ID情報
  • DOI : 10.1182/bloodadvances.2017013953
  • PubMed ID : 29720492
  • PubMed Central 記事ID : PMC5941997

エクスポート
BibTeX RIS